Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model.

BACKGROUND We studied whether blocking of the T cell costimulatory signal from B7-->CD28 by cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein would, either by itself or when added to methotrexate/cyclosporine, result in improved graft-versus-host disease prevention after dog leukocyte antigen nonidentical canine hematopoietic stem cell transplantation after 920 cGy total body irradiation. RESULTS AND CONCLUSIONS Survivals of cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein-treated dogs were only slightly prolonged over controls. It appeared that the addition of cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein failed to induce graft-host tolerance in this model beyond that achieved with methotrexate/cyclosporine alone.

[1]  M. Zand,et al.  Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. , 1998, Transplantation.

[2]  R. Storb,et al.  DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. , 1998, Tissue antigens.

[3]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[4]  H. Deeg,et al.  Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. , 1998, Blood.

[5]  C. Anasetti,et al.  Role of CD28 in acute graft-versus-host disease. , 1998, Blood.

[6]  G. Szot,et al.  Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. , 1997, Journal of immunology.

[7]  T. Mak,et al.  Acute graft-versus-host disease without costimulation via CD28. , 1997, Transplantation.

[8]  H. Deeg,et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. , 1997, Blood.

[9]  A. Gratwohl,et al.  A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT) , 1997, Bone Marrow Transplantation.

[10]  N. Srinivas,et al.  A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. , 1997, Journal of pharmaceutical and biomedical analysis.

[11]  C. Fathman,et al.  Induction of tolerance to small bowel allografts in high-responder rats by combining anti-CD4 with CTLA4Ig. , 1996, Transplantation.

[12]  P. Linsley,et al.  CTLA4Ig inhibits alloantibody responses to repeated blood transfusions. , 1996, Blood.

[13]  R. Storb,et al.  Molecular analysis of DLA-DRBB1 polymorphism. , 1996, Tissue antigens.

[14]  J. Fay,et al.  FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. , 1996, Blood.

[15]  P. Linsley,et al.  CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers. , 1994, Transplantation.

[16]  E. Bryant,et al.  USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING , 1994, Transplantation.

[17]  P. Linsley,et al.  Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.

[18]  P. Linsley,et al.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion , 1993, The Journal of experimental medicine.

[19]  H. Deeg,et al.  FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS , 1993, Transplantation.

[20]  H. Deeg,et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? , 1993, Blood.

[21]  C Anasetti,et al.  Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.

[22]  Pepe,et al.  Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. , 1993, Blood.

[23]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[25]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[26]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[27]  Choongrak Kim,et al.  Exact Properties of Some Exact Test Statistics for Comparing Two Binomial Proportions , 1990 .

[28]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.

[29]  H. Deeg,et al.  FAILURE OF ALLOGENEIC CANINE MARROW GRAFTS AFTER TOTAL‐BODY IRRADIATION: ALLOGENEIC “RESISTANCE” VERSUS TRANSFUSION‐INDUCED SENSITIZATION , 1986, Transplantation.

[30]  H. Deeg,et al.  Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. , 1986, Blood.

[31]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[32]  H. Deeg,et al.  Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes. , 1982, The American journal of pathology.

[33]  R. Storb,et al.  TREATMENT OF CANINE GRAFT-VERSUS-HOST DISEASE WITH METHOTREXATE AND CYCLOPHOSPHAMIDE FOLLOWING BONE MARROW TRANSPLANTATION FROM HISTOINCOMPATIBLE DONORS , 1970, Transplantation.